Exact Mass: 482.07687580000004
Exact Mass Matches: 482.07687580000004
Found 33 metabolites which its exact mass value is equals to given mass value 482.07687580000004,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
3,4,5,11,12,13,21,22,23-nonahydroxy-9,14,17-trioxatetracyclo[17.4.0.0(2),.0(1),(1)]tricosa-1(23),2,4,6,19,21-hexaene-8,18-dione
6,7,8,11,12,13,21,22,23-nonahydroxy-2,17,20-trioxatetracyclo[17.3.1.0,.0(1),(1)]tricosa-4,6,8,10,12,14-hexaene-3,16-dione
Regorafenib
C21H15ClF4N4O3 (482.07687580000004)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity[1].
2-(alpha-Hydroxypropyl)thiamine diphosphate; 2-Hydroxypropyl-ThPP
4,6-(S)-HHDP-D-glucose|4,6-O-((S)-4,4,5,5,6,6-hexahydroxydiphenoyl)-D-glucose|4,6-O-<(S)-4,4,5,5,6,6-hexahydroxydiphenoyl>-D-glucose
2-(4-(2-((3-(5-(Pyridin-2-Ylthio)thiazol-2-Yl)ureido)methyl)-1h-Imidazol-4-Yl)phenoxy)acetic Acid
Regorafenib
C21H15ClF4N4O3 (482.07687580000004)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity[1].
2,3-Dihydroxybenzoyl 5-adenylate(1-)
C17H17N5O10P- (482.07130120000005)
Conjugate base of 2,3-dihydroxybenzoyl 5-adenylate.
(3,4-Dihydroxybenzoate)adenylate
C17H17N5O10P- (482.07130120000005)
(10r,11r,13r,14r,15s)-3,4,5,11,14,20,21,22-octahydroxy-13-(hydroxymethyl)-9,12,16-trioxatetracyclo[16.4.0.0²,⁷.0¹⁰,¹⁵]docosa-1(18),2,4,6,19,21-hexaene-8,17-dione
(10r,11s,13r,14r,15s)-3,4,5,11,14,20,21,22-octahydroxy-13-(hydroxymethyl)-9,12,16-trioxatetracyclo[16.4.0.0²,⁷.0¹⁰,¹⁵]docosa-1(18),2,4,6,19,21-hexaene-8,17-dione
2,3-hexahydroxydiphenyl-D-glucose
{"Ingredient_id": "HBIN004100","Ingredient_name": "2,3-hexahydroxydiphenyl-D-glucose","Alias": "NA","Ingredient_formula": "C20H18O14","Ingredient_Smile": "C1=C2C(=C(C(=C1O)O)O)C3=C(C(=C(C=C3C(=O)OC4C(C(C(OC4O)CO)O)OC2=O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "42628","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2,3-o-(s)-hexahydroxydiphenoyl-d-gluco-pyranose
{"Ingredient_id": "HBIN004147","Ingredient_name": "2,3-o-(s)-hexahydroxydiphenoyl-d-gluco-pyranose","Alias": "NA","Ingredient_formula": "C20H18O14","Ingredient_Smile": "C1=C2C(=C(C(=C1O)O)O)C3=C(C(=C(C=C3C(=O)OC4C(C(C(OC4O)CO)O)OC2=O)O)O)O","Ingredient_weight": "482.3 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15749","TCMID_id": "9501","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "14035453","DrugBank_id": "NA"}